Investigational Drug Information for Eritoran
✉ Email this page to a colleague
What is the development status for investigational drug Eritoran?
Eritoran is an investigational drug.
There have been 5 clinical trials for Eritoran.
The most recent clinical trial was a Phase 3 trial, which was initiated on April 11th 2016.
The most common disease conditions in clinical trials are Insulin Resistance, Hypersensitivity, and Sepsis. The leading clinical trial sponsors are Eisai Inc., The University of Texas Health Science Center at San Antonio, and UMC Utrecht.
There are seventeen US patents protecting this investigational drug and four hundred and fifty-four international patents.
Summary for Eritoran
| US Patents | 17 |
| International Patents | 454 |
| US Patent Applications | 131 |
| WIPO Patent Applications | 90 |
| Japanese Patent Applications | 33 |
| Clinical Trial Progress | Phase 3 (2016-04-11) |
| Vendors | 17 |
Recent Clinical Trials for Eritoran
| Title | Sponsor | Phase |
|---|---|---|
| Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia | Australian and New Zealand Intensive Care Research Centre | Phase 4 |
| Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia | Berry Consultants | Phase 4 |
| Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia | Global Coalition for Adaptive Research | Phase 4 |
Clinical Trial Summary for Eritoran
Top disease conditions for Eritoran
Top clinical trial sponsors for Eritoran
US Patents for Eritoran
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Eritoran | ⤷ Sign Up | Combination therapy for inducing immune response to disease | IBC Pharmaceuticals, Inc. (Morris Plains, NJ) | ⤷ Sign Up |
| Eritoran | ⤷ Sign Up | Methods for treating renal disease | Beth Israel Deaconess Medical Center, Inc. (Boston, MA) | ⤷ Sign Up |
| Eritoran | ⤷ Sign Up | Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors | IBC Pharmaceuticals, Inc. (Morris Plains, NJ) | ⤷ Sign Up |
| Eritoran | ⤷ Sign Up | Combination therapy for inducing immune response to disease | IBC Pharmaceuticals, Inc. (Morris Plains, NJ) | ⤷ Sign Up |
| Eritoran | ⤷ Sign Up | Disease therapy by inducing immune response to Trop-2 expressing cells | IBC Pharmaceuticals, Inc. (Morris Plains, NJ) | ⤷ Sign Up |
| Eritoran | ⤷ Sign Up | Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1 | Immunomedics, Inc. (Morris Plains, NJ) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Eritoran
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Eritoran | Australia | AU2014228886 | 2033-03-15 | ⤷ Sign Up |
| Eritoran | Canada | CA2942514 | 2033-03-15 | ⤷ Sign Up |
| Eritoran | European Patent Office | EP2970428 | 2033-03-15 | ⤷ Sign Up |
| Eritoran | Hong Kong | HK1220699 | 2033-03-15 | ⤷ Sign Up |
| Eritoran | Japan | JP2016516053 | 2033-03-15 | ⤷ Sign Up |
| Eritoran | World Intellectual Property Organization (WIPO) | WO2014144686 | 2033-03-15 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
